RxDoctor Payments Data

Richard Watson, MD

Cardiovascular Disease · Morristown, NJNPI 1003814039

Payments from drug & device makers

$27,021in general payments, 2019–2025

Across 170 payments — averaging $158.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$25K
  • Novartis$518
  • Amgen$406
  • Pfizer$198
  • Merck$164
  • Johnson & Johnson$93
  • plus $615 from 17 others

What the payments were for

  • Consulting fees$1,2004%
  • Speaking & faculty fees$21,08578%
  • Travel & lodging$2,0678%
  • Food & beverage$2,66910%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,021 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$183,193
Medicare patients
454
Services billed
2,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban269$360,852
XareltoRivaroxaban72$91,611
MultaqDronedarone Hcl43$86,381
EntrestoSacubitril/Valsartan58$77,608
VascepaIcosapent Ethyl81$62,012
Repatha SureclickEvolocumab44$36,546
JardianceEmpagliflozin22$35,104
Icosapent Ethyl71$31,296
Repatha PushtronexEvolocumab24$16,136
Praluent PenAlirocumab18$11,176
Ezetimibe364$10,427
Rosuvastatin Calcium674$10,098
Metoprolol Succinate433$7,742
CrestorRosuvastatin Calcium15$6,020
Atorvastatin Calcium548$5,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$198$360,852269 claims
Johnson & JohnsonXarelto$93$91,61172 claims
Sanofi-aventis U.S. LLCMultaq$73$86,38143 claims
NovartisEntresto$518$77,60858 claims
Boehringer IngelheimJardiance$37$35,10422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →